DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Propafenone (Propafenone Hydrochloride) - Indications and Dosage



In patients without structural heart disease, propafenone is indicated to prolong the time to recurrence of

  • –paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms.
  • –paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms.

As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended.

The use of propafenone HCl in patients with chronic atrial fibrillation has not been evaluated. Propafenone HCl should not be used to control ventricular rate during atrial fibrillation.

Propafenone HCl is also indicated for the treatment of

  • –documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone HCl, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks.

Initiation of propafenone HCl treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital.

Propafenone HCl, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias.


The dose of propafenone HCl must be individually titrated on the basis of response and tolerance. It is recommended that therapy be initiated with 150 mg propafenone given every eight hours (450 mg/day). Dosage may be increased at a minimum of 3 to 4 day intervals to 225 mg every 8 hours (675 mg/day) and, if necessary, to 300 mg every 8 hours (900 mg/day). The usefulness and safety of dosages exceeding 900 mg per day have not been established. In those patients in whom significant widening of the QRS complex or second or third degree AV block occurs, dose reduction should be considered.

As with other antiarrhythmic agents, in the elderly or in ventricular arrhythmia patients with marked previous myocardial damage, the dose of propafenone HCl should be increased more gradually during the initial phase of treatment.


Propafenone hydrochloride tablets are supplied as follows:

Propafenone hydrochloride tablets 150 mg, white, round, scored, film-coated, debossed MP 511

Bottles of 20 NDC 54868-4770-2
Bottles of 30 NDC 54868-4770-5
Bottles of 60 NDC 54868-4770-1
Bottles of 90 NDC 54868-4770-4
Bottles of 100 NDC 54868-4770-3

Propafenone hydrochloride tablets 225 mg, white, round, scored, film-coated, debossed MP 512

Bottles of 30 NDC 54868-5950-1
Bottles of 90 NDC 54868-5950-0
Bottles of 60
NDC 54868-5950-2

Store at 20° to 25°C (68° to 77°F).

[See USP Controlled Room Temperature]


Manufactured by:
Philadelphia, PA 19124 USA

Rev 01, May 2009

Relabeling and Repackaging by:

Physicians Total Care, Inc.
Tulsa, OK     74146

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017